{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T20:33:51Z","timestamp":1775680431348,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T00:00:00Z","timestamp":1504742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T00:00:00Z","timestamp":1504742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["No. 2180"],"award-info":[{"award-number":["No. 2180"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s10157-017-1463-0","type":"journal-article","created":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T08:44:19Z","timestamp":1504773859000},"page":"318-327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Importance of glomerular filtration rate change as surrogate endpoint for the future incidence of end-stage renal disease in general Japanese population: community-based cohort study"],"prefix":"10.1007","volume":"22","author":[{"given":"Eiichiro","family":"Kanda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kashihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiho","family":"Iseki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunitoshi","family":"Iseki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,7]]},"reference":[{"key":"1463_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","unstructured":"Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89\u201395.","journal-title":"Clin Pharmacol Ther"},{"key":"1463_CR2","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1001\/jama.2014.6634","volume":"311","author":"J Coresh","year":"2014","unstructured":"Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS, CKD Prognosis Consortium. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518\u201331.","journal-title":"JAMA"},{"key":"1463_CR3","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1053\/j.ajkd.2014.08.017","volume":"64","author":"LA Inker","year":"2014","unstructured":"Inker LA, Lambers Heerspink HJ, Mondal H, Schmid CH, Tighiouart H, Noubary F, Coresh J, Greene T, Levey AS. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials. Am J Kidney Dis. 2014;64:848\u201359.","journal-title":"Am J Kidney Dis"},{"key":"1463_CR4","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1053\/j.ajkd.2014.08.018","volume":"64","author":"HJ Lambers Heerspink","year":"2014","unstructured":"Lambers Heerspink HJ, Tighiouart H, Sang Y, Ballew S, Mondal H, Matsushita K, Coresh J, Levey AS, Inker LA. GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials. Am J Kidney Dis. 2014;64:860\u20136.","journal-title":"Am J Kidney Dis"},{"key":"1463_CR5","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1053\/j.ajkd.2014.08.019","volume":"64","author":"T Greene","year":"2014","unstructured":"Greene T, Teng CC, Inker LA, Redd A, Ying J, Woodward M, Coresh J, Levey AS. Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study. Am J Kidney Dis. 2014;64:867\u201379.","journal-title":"Am J Kidney Dis"},{"key":"1463_CR6","doi-asserted-by":"publisher","first-page":"e0132927","DOI":"10.1371\/journal.pone.0132927","volume":"10","author":"WX Chang","year":"2015","unstructured":"Chang WX, Asakawa S, Toyoki D, Nemoto Y, Morimoto C, Tamura Y, Ota T, Shibata S, Fujigaki Y, Shen ZY, Uchida S. Predictors and the subsequent risk of end-stage renal disease\u2014usefulness of 30% decline in estimated GFR over 2 years. PLoS ONE. 2015;10:e0132927.","journal-title":"PLoS ONE"},{"key":"1463_CR7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","volume":"64","author":"AS Levey","year":"2014","unstructured":"Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64:821\u201335.","journal-title":"Am J Kidney Dis"},{"key":"1463_CR8","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.kint.2016.08.003","volume":"90","author":"K Matsushita","year":"2016","unstructured":"Matsushita K, Chen J, Sang Y, Ballew SH, Shimazaki R, Fukagawa M, Imai E, Coresh J, Hishida A. Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate. Kidney Int. 2016;90:1109\u201314.","journal-title":"Kidney Int"},{"issue":"7 Suppl 2","key":"1463_CR9","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1097\/01.ASN.0000070153.91733.09","volume":"14","author":"K Iseki","year":"2003","unstructured":"Iseki K. The okinawa screening program. J Am Soc Nephrol. 2003;14(7 Suppl 2):S127\u201330.","journal-title":"J Am Soc Nephrol"},{"key":"1463_CR10","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1046\/j.1523-1755.2003.00868.x","volume":"63","author":"K Iseki","year":"2003","unstructured":"Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468\u201374.","journal-title":"Kidney Int"},{"key":"1463_CR11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/hr.2013.11","volume":"36","author":"K Iseki","year":"2013","unstructured":"Iseki K, Iseki C, Kinjo K. Changes in serum uric acid have a reciprocal effect on eGFR change: a 10-year follow-up study of community-based screening in Okinawa, Japan. Hypertens Res. 2013;36:650\u20134.","journal-title":"Hypertens Res"},{"key":"1463_CR12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S0272-6386(04)01080-7","volume":"44","author":"K Iseki","year":"2004","unstructured":"Iseki K, Kinjo K, Iseki C, Takishita S. Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis. 2004;44:806\u201314.","journal-title":"Am J Kidney Dis"},{"key":"1463_CR13","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"1463_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s10157-007-0463-x","volume":"11","author":"E Imai","year":"2007","unstructured":"Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, Ura N, Kiyohara Y, Hirakata H, Moriyama T, Ando Y, Nitta K, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11:156\u201363.","journal-title":"Clin Exp Nephrol"},{"key":"1463_CR15","unstructured":"International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline statistical principles for clinical trials E9. 1998; \n                    http:\/\/www.ich.org\/products\/guidelines\/efficacy\/efficacy-single\/article\/statistical-principles-for-clinical-trials.html\n                    \n                  . Accessed 24 Aug 2017."},{"key":"1463_CR16","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1093\/ndt\/gfs263","volume":"27","author":"TC Turin","year":"2012","unstructured":"Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, Matsushita K, Hemmelgarn BR. Short-term change in kidney function and risk of end-stage renal disease. Nephrol Dial Transplant. 2012;27:3835\u201343.","journal-title":"Nephrol Dial Transplant"},{"key":"1463_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.kint.2016.09.038","volume":"91","author":"CM Clase","year":"2017","unstructured":"Clase CM, Barzilay J, Gao P, Smyth A, Schmieder RE, Tobe S, Teo KK, Yusuf S, Mann JF. Acute change in glomerular filtration rate with inhibition of the renin\u2013angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int. 2017;91:683\u201390.","journal-title":"Kidney Int"},{"key":"1463_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/archinte.164.6.659","volume":"164","author":"DS Keith","year":"2004","unstructured":"Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659\u201363.","journal-title":"Arch Intern Med"},{"key":"1463_CR19","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1681\/ASN.2005101122","volume":"17","author":"CA Peralta","year":"2006","unstructured":"Peralta CA, Shlipak MG, Fan D, Ordo\u00f1ez J, Lash JP, Chertow GM, Go AS. Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol. 2006;17:2892\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"1463_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1681\/ASN.2004030203","volume":"16","author":"R Foley","year":"2005","unstructured":"Foley R, Murray A, Li S, Herzog C, McBean A, Eggers P, Collins A. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489\u201395.","journal-title":"J Am Soc Nephrol"},{"key":"1463_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1681\/ASN.2010020194","volume":"22","author":"C Forsblom","year":"2011","unstructured":"Forsblom C, Harjutsalo V, Thorn LM, Wad\u00e9n J, Tolonen N, Saraheimo M, Gordin D, Moran JL, Thomas MC, Groop PH, FinnDiane Study Group. Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol. 2011;22:537\u201344.","journal-title":"J Am Soc Nephrol"},{"key":"1463_CR22","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1056\/NEJMc1110239","volume":"365","author":"KS Rogacev","year":"2011","unstructured":"Rogacev KS, Bittenbring JT, Fliser D. Bardoxolone methyl, chronic kidney disease, and type 2 diabetes. N Engl J Med. 2011;365:1745\u20136 (author reply 1746\u20137).","journal-title":"N Engl J Med."},{"key":"1463_CR23","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1053\/j.ajkd.2009.12.016","volume":"55","author":"K Matsushita","year":"2010","unstructured":"Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis. 2010;55:648\u201359.","journal-title":"Am J Kidney Dis"},{"key":"1463_CR24","first-page":"898","volume":"21","author":"B Bernieh","year":"2010","unstructured":"Bernieh B, Al Hakim MR, Boobes Y, Abu Zidan FM. Fasting Ramadan in chronic kidney disease patients: clinical and biochemical effects. Saudi J Kidney Dis Transplant. 2010;21:898\u2013902.","journal-title":"Saudi J Kidney Dis Transplant"},{"key":"1463_CR25","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.2215\/CJN.04940516","volume":"11","author":"T Melsom","year":"2016","unstructured":"Melsom T, Stefansson V, Schei J, Solbu M, Jenssen T, Wilsgaard T, Eriksen BO. Association of increasing GFR with change in albuminuria in the general population. Clin J Am Soc Nephrol. 2016;11:2186\u201394.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1463_CR26","unstructured":"Ministry of Health, Labour and Welfare of Japan. Ethical guidelines for medical and health research involving human subjects. 2017;\n                     http:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/hokabunya\/kenkyujigyou\/i-kenkyu\/index.html\n                    \n                  . Accessed 24 Aug 2017 (in Japanese)."}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-017-1463-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-017-1463-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-017-1463-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T09:39:27Z","timestamp":1589449167000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-017-1463-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,7]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["1463"],"URL":"https:\/\/doi.org\/10.1007\/s10157-017-1463-0","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,7]]},"assertion":[{"value":"27 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This research is partially supported by the Research on Regulatory Science of Pharmaceuticals and Medical Devices from Japan Agency for Medical Research and Development, AMED. All authors have declared no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the JSN at which the studies were conducted (approval number 35) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was performed according to Ethical Guidelines for Medical and Health Research Involving Human Subjects enacted by Ministry of Health, Labour and Welfare of Japan []. Since it is difficult to obtain written or oral informed consent from the study subjects who participated between 1993 and 1996, and information provided from Okinawa Health Promotion Foundation was anonymized, the investigators shall not necessarily be required to obtain informed consent according to the guideline.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}]}}